After almost two decades of misguided policies based entirely upon pharmaceutical propaganda, the NIH and CDC have convinced the Obama Administration to ask state officials to drop the criminal prosecution of allegedly HIV+ Americans. This decision comes only nine months after OMSJ began to force prosecutors to prove that HIV tests detect HIV. Continue reading ‘OMSJ Prompts Nat’l HIV Policy Change in Nine Months’
Tag Archive for 'NIH'
The word is chutzpa – and it’s hard to imagine a better way to describe UC Berkeley (UCB) Vice Provost Sheldon Zedeck’s assignment of Arthur Reingold to investigate misconduct allegations against Professor Peter Duesberg, PhD. The charges stem from Duesberg’s (et al) report that was published in 2009 by Medical Hypotheses. Citing 35 references that includes South Africa’s (SA) own mortality reports, Prof. Duesberg’s team concluded that: Continue reading ‘The Berkeley Inquisition Exposed’
AHRP reports that history is about to repeat itself:
In the 1976 swine flu vaccine program, 40 million people were vaccinated with an inadequately tested vaccine. The government gave the vaccine manufacturers immunity from liability, but created an alternative compensation program. Five thousand people sought benefits for vaccine injuries.
Today, as in 1976, official concern has focused on flu vaccine availability without regard for the safety of an H1N1 vaccine. Many national regulatory agencies have set-up fast-track approval processes for the H1N1 vaccine, which means that a vaccine might be licensed without the usual safety and efficacy data requirements. Vaccine safety will therefore have to be monitored through post-marketing surveillance.
But there is reason for concern that we will repeat the debacle of the 1976 H1N1 outbreak in the USA, where mass vaccination was associated with complications, which stopped the campaign and led to the withdrawal of the vaccine.
What’s more, today, the government has NOT established an ALTERNATIVE COMPENSATION PROGRAM – as it had in 1976. The existing vaccine compensation program covers only designated vaccines and does NOT cover most adult vaccines.
The U.S. government has adopted (what critics regard) a reckless policy encouraging (if not mandating) the use of untested controversial vaccines with novel adjuvants likely to be used to strengthen vaccines and stretch the supply–they are named MF59 (Novartis) and ASO3 (Glaxo Smith-Kline). Only 3 vaccines using these adjuvants have been licensed in Europe, and none have been given a license in the US.
It is likely that these adjuvants will cause far more damage and autoimmune illness than the swine vaccine used in 1976.
Indeed, manufacturers have been given immunity from liability, as have the government program planners. But no compensation mechanism has been created for citizens who are likely to suffer harm. This is but a tacit acknowledgement that the vaccines are likely to produce harm.
The New York Times reports that pharmaceutical company ghostwriters played a major role in producing 26 scientific papers that backed the use of hormone replacement therapy in women, suggesting that the level of hidden industry influence on medical literature is broader than previously known.
The articles, published in medical journals between 1998 and 2005, emphasized the benefits and de-emphasized the risks of taking hormones to protect against maladies like aging skin, heart disease and dementia. That supposed medical consensus benefited Wyeth, the pharmaceutical company that paid a medical communications firm to draft the papers, as sales of its hormone drugs, called Premarin and Prempro, soared to nearly $2 billion in 2001.
But the seeming consensus fell apart in 2002 when a huge federal study on hormone therapy was stopped after researchers found that menopausal women who took certain hormones had an increased risk of invasive breast cancer, heart disease and stroke. A later study found that hormones increased the risk of dementia in older patients.
The ghostwritten papers were typically review articles, in which an author weighs a large body of medical research and offers a bottom-line judgment about how to treat a particular ailment. The articles appeared in 18 medical journals, including The American Journal of Obstetrics and Gynecology and The International Journal of Cardiology.
The articles did not disclose Wyeth’s role in initiating and paying for the work. Elsevier, the publisher of some of the journals, said it was disturbed by the allegations of ghostwriting and would investigate.
The documents on ghostwriting were uncovered by lawyers suing Wyeth and were made public after a request in court from PLoS Medicine, a medical journal from the Public Library of Science, and The New York Times.
A spokesman for Wyeth said that the articles were scientifically accurate and that pharmaceutical companies routinely hired medical writing companies to assist authors in drafting manuscripts. (Story here)
Although the reporting of this story by the NYT is new, the practice is not. According to former Eli Lilly marketing executive John Virapen, fake stories and reports are part of the overall marketing strategy throughout the pharmaceutical industry. Because the industry funds the FDA, CDC and NIH officials, no one investigates the corruption because they profit from them.
As a result, thousands of people are unnecessarily killed or injured from adverse drug reactions. In the case of Prozac or hormone replacement therapy, the eventual lawsuits are merely part of the cost of doing business. If a drug like Prozac generates $10 billion in profits over 20 years and generates $4 billion in lawsuits (with confidentiality agreements), the $6 billion net profit makes it worthwhile.
The problem is not that the pharmaceutical industry harms and kills patients millions of patients for profit, but that there are no competent investigative agencies or politicians who aren’t paid to ignore the mayhem.
In this related story, pharmaceutical lobbyists have successfully pressured White House officials to stand by their behind-the-scenes deal to block Congressional efforts to extract more than their agreed-upon $80 billion.